| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
854.96(M) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,241 |
| 52
Week Range: |
$1.63 - $6.34 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Boothe Douglas |
President, Generics Division |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(41,756) |
0 |
|
- |
|
| Boothe Douglas |
President, Generics Division |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,145) |
0 |
|
- |
|
| Buchi J Kevin |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,281) |
0 |
|
- |
|
| Buchi J Kevin |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,020) |
0 |
|
- |
|
| Pendergast Mary K |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,408) |
0 |
|
- |
|
| Pendergast Mary K |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,942) |
0 |
|
- |
|
| Terreri Peter R |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,408) |
0 |
|
- |
|
| Terreri Peter R |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(43,129) |
0 |
|
- |
|
| Nestor Michael |
President, Impax Specialty |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(19,728) |
0 |
|
- |
|
| Nestor Michael |
President, Impax Specialty |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(56,796) |
0 |
|
- |
|
| Burr Robert L |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,408) |
0 |
|
- |
|
| Burr Robert L |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(6,057) |
0 |
|
- |
|
| Burr Robert L |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(55,067) |
0 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(18,135) |
0 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(50,116) |
0 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,566) |
0 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• – – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(53,423) |
0 |
|
- |
|
| Benet Leslie Z |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,742) |
0 |
|
- |
|
| Benet Leslie Z |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(600) |
0 |
|
- |
|
| Benet Leslie Z |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,741) |
0 |
|
- |
|
| Chao Allen |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,408) |
0 |
|
- |
|
| Chao Allen |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(316,000) |
0 |
|
- |
|
| Chao Allen |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(64,037) |
0 |
|
- |
|
| Vergis Janet S. |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,508) |
0 |
|
- |
|
| Vergis Janet S. |
Director |
– • – |
2018-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,642) |
0 |
|
- |
|
531 Records found
|
|
Page 1 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (0.92%) 
